Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine by 源��꽭二� et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Neuropsychobiology 2010;62:198–206  
 DOI: 10.1159/000319362 
 Serotonin Transporter Gene
Polymorphism Associated with Short-Term
Treatment Response to Venlafaxine 
 Sang-Hyuk Lee  a    Tae Kyou Choi  b    Eun Lee  b    Jeong-Ho Seok  b    Sung Hee Lee  c    
Hong Shick Lee  b    Se Joo Kim  b     
 a   Department of Psychiatry, CHA Bundang Medical Center, CHA University School of Medicine,  Seongnam , and 
 b   Department of Psychiatry and Institute of Behavioural Science in Medicine and  c   Department of Pharmacology,
Yonsei University College of Medicine,  Seoul , South Korea
 
MADRS) to venlafaxine at week 4 was associated with the 
non-s/s (l/l and l/s) genotype of 5-HTTLPR; (2) in repeated 
measures ANOVA, the BDI, MADRS and HAM-A scores de-
creased more significantly in patients with the non-s/s geno-
type than in those with the s/s genotype, and (3) multiple 
regression analyses suggested that the 5-HTTLPR polymor-
phism is a predictive factor for short-term treatment re-
sponse to venlafaxine. However, 5-HTTVNTR showed no sig-
nificant association with treatment response to venlafaxine. 
Both 5-HTTLPR and 5-HTTVNTR were not associated with 
side effects of venlafaxine.  Conclusion: The 5-HTTLPR non-
s/s genotype can be associated with venlafaxine treatment 
responses. However, further large-scale studies are warrant-
ed to confirm this finding.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 In psychiatry, finding the predictors of antidepressant 
response is important in clinical practice. Given that the 
serotonin transporter can play a role in the functional 
modulation of serotonin, many researchers ask if poly-
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 Abstract 
 Background: Polymorphisms of serotonin transporter, es-
pecially serotonin transporter linked promoter region (5-
HTTLPR) and serotonin transporter intron 2 variable number 
tandem repeat (5-HTTVNTR), have been suggested to be as-
sociated with treatment response to selective serotonin 
reuptake inhibitors. However, there have been only few re-
ports of the association between 5-HTTLPR or 5-HTTVNTR 
and treatment response to venlafaxine.  Methods: 84 Korean 
major depressive disorder patients were included in this 
study. They were administered 75 mg of venlafaxine XR (ex-
tended release) for 1 week and then took 150 mg for the next 
3 weeks. All patients were evaluated at baseline and week 4 
by the Hamilton Depression Rating Scale (HAM-D), Mont-
gomery-Åsberg Depression Rating Scale (MADRS), Beck De-
pression Inventory (BDI), Hamilton Anxiety Rating Scale 
(HAM-A), and Beck Anxiety Inventory (BAI).  Results: (1) Treat-
ment response of depressive symptoms (BDI, HAM-D, 
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morphisms of the serotonin transporter (5-HTT) gene 
could predict the treatment response to selective sero-
tonin reuptake inhibitors (SSRI). To date, a number of 
studies about the relationship between several genetic 
variants in 5-HTT and treatment response to SSRI have 
been reported, but it is still controversial. Among those 
genetic variants of 5-HTT, the serotonin transporter 
linked promoter region (5-HTTLPR) polymorphism and 
5-HTT intron 2 variable number tandem repeat (5-
HTTVNTR) are most widely studied.
 Some researchers insist that the l/l genotype or l-allele 
of the 5-HTTLPR gene is associated with treatment re-
sponse to SSRI  [1–3] . Corroboration by other researchers 
and meta-analysis also support these findings  [4] . How-
ever, there also exist negative findings  [5] . Moreover,
in Asian studies, the direction of the effect of the 5-
HTTLPR polymorphism on treatment response to SSRI 
indicated contradictory results. Several studies  [6–8] 
have shown that contrary to Caucasian populations, the 
s/s genotype or s-allele of 5-HTTLPR is associated with a 
better treatment response to SSRI. However, others  [9] 
have shown that the l/l genotype is associated with a bet-
ter treatment response.
 There are several reports regarding the association be-
tween 5-HTTLPR and SSRI side effects. Carriers of the 
s-allele treated with paroxetine exhibit reduced tolerabil-
ity and higher discontinuation rates compared to l/l ho-
mozygotes  [10] , and the s-variant was associated with side 
effects induced by SSRI  [11] . Furthermore, the s-allele was 
shown to identify patients at risk for developing insomnia 
and agitation with fluoxetine treatment  [12] . Other stud-
ies reported no association between 5-HTTLPR and ad-
verse effects induced by SSRI  [13, 14] .
 5-HTTVNTR has been addressed less than 5-HTTL-
PR. Min et al.  [15] reported that depressive patients with 
the 12/12 repeats of 5-HTTVNTR or the l/l genotype of 
5-HTTLPR experienced a better clinical response to SSRI 
or serotonin norepinephrine reuptake inhibitors (SNRI). 
One Korean study also showed that major depressive dis-
order (MDD) patients that were homozygous for 12/12 
repeats of 5-HTTVNTR or the s/s of 5-HTTLPR showed 
better responses than all others  [7] .
 However, only a limited number of pharmacokinetic 
genetic studies reported the relationship between SNRI, 
which are frequently used in clinical practice, and se-
rotonin transporter polymorphisms. No influence of 5-
HTTLPR polymorphisms on the antidepressant response 
to milnacipran was detected. In contrast, the presence of 
the T allele of the NET T–182C polymorphism was asso-
ciated with a superior milnacipran response  [16] . Recent-
ly, two Japanese studies showed that the C allele of –1297 
C ] G   2 -adrenergic receptor and the Met/Met genotype 
of COMT Val158Met polymorphisms are associated with 
better or faster response to milnacipran  [17, 18] . And al-
though the study sample did not consist of depressive pa-
tients, the response in venlafaxine-treated obsessive-
compulsive disorder patients has been reported to be 
 associated with the l/s genotype of 5-HTTLPR  [19] . 
Therefore, we investigated whether an association exists 
between venlafaxine and serotonin transporter gene 
polymorphisms in patients with MDD.
 Methods 
 Subjects 
 A total of 101 patients with MDD were recruited from 3 gen-
eral hospitals over a period of 24 months from July 2006 to De-
cember 2008. All the patients were Korean, met the DSM-IV cri-
teria for MDD and were diagnosed by the Structural Clinical In-
terview for DSM-IV. Patients with other axis I disorders 
(including dementia, substance abuse, panic disorder, obsessive-
compulsive disorder and generalized anxiety disorder) and those 
with axis II disorders, determined by a clinical interview, were 
excluded. Patients with a history of seizure, brain trauma, cardio-
vascular disorders or significant physical or neurological disor-
ders were also excluded. The ages of the patients ranged from 20 
to 69 years and all had been free of psychotropic drugs for at least 
14 days prior to their entry into the study. All study procedures 
complied with the institutional review board regulations and 
were conducted in accordance with the Declaration of Helsinki 
and the principles of Good Clinical Practice. After a complete 
description of the study to the subjects, written informed consent 
was obtained.
 During the treatment period, venlafaxine was administered to 
all patients daily (in the morning after breakfast at the same dose) 
for 4 weeks. The initial total dose was 75 mg/day, which after 1 
week was increased to 150 mg/day. Additionally, administration 
of lorazepam (0.5 mg) at bedtime was permitted once per week to 
patients with insomnia. No other psychotropic drugs were per-
mitted during the study. All types of psychotherapies other than 
brief supportive psychotherapy were not permitted as well.
 Genotyping 
 Peripheral blood was collected and genomic DNA extracted 
using standard procedures  [20] . The region containing the 5-
HTTLPR polymorphism was amplified by PCR using the for-
ward primer 5  -GGCGGTGCCGCTCTGAATGC-3  and the re-
verse primer 5  -GAGGGACTGAGCTGGACAACAAC-3  , ac-
cording to a previously described protocol  [21] . The long (528 bp) 
and short (484 bp) PCR-amplified 5-HTTLPR alleles were sepa-
rated by electrophoresis on 3% agarose gels supplemented with 
ethidium bromide and visualized by silver staining.
 Genotyping of 5-HTTVNTR was carried out according to the 
method previously described  [22] . The primers 8,224 (5  -GTC-
AGTATCACAGGCTGCGAG) and 8,223 (5  -TGTTCC TAG TC-
TTACGCCAGTG) were used. These primer pairs amplify across 
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the VNTR region of intron 2 that contains the 17-bp repetitive 
element. PCR was performed in a final volume of 25   l containing 
50 ng of genomic DNA, 0.2 m M dNTPs, 10 pmol of each primer, 
10 m M Tris-HCl (pH 8.3), 50 m M KCl, 1.5 m M MgCl 2 , 0.01% gela-
tine and 1 U of Taq DNA polymerase. The PCR amplification 
consisted of 35 cycles at 95   °   C (1 min), 58   °   C (1 min) and 72   °   C
(1 min). Amplified fragments were resolved on 3% agarose gels, 
and bands were visualized by ethidium bromide staining and
ultraviolet transillumination. The genotyping success rates for 
both 5-HTTLPR and 5-HTTVNTR were 100%.
 Assessments 
 The Hamilton Anxiety Rating Scale (HAM-A)  [23] , Beck Anx-
iety Inventory (BAI)  [24] , Hamilton Depression Rating Scale 
(HAM-D)  [25] , Montgomery-Åsberg Depression Rating Scale 
(MADRS)  [26] and Beck Depression Inventory (BDI)  [27] were 
used to evaluate patients at baseline, and after 1 and 4 weeks of 
treatment. The interrater reliability was 0.80–0.84 for the HAM-
A and HAM-D.
 Responders were defined by a reduction from baseline in the 
depressive or anxiety symptom scale score of at least 50%, and 
remitters were defined by a HAM-D total score of 7 points or less 
after 4 weeks of treatment. We measured the side effects of ven-
lafaxine treatment using the Toronto Side Effect Scale  [28] . For 
each side effect, we classified the patients into a side effect group 
and a non-side-effect group. If the patients experienced any 
kinds of side effects at any time during the 4 treatment periods, 
we included them into the side effect group. Because of the lim-
ited statistical power, we compared the genotype and allelic dif-
ferences between the 2 groups only in the side effects that oc-
curred in more than 15% of the participants who completed this 
study.
 Drug compliance was judged using a self-report checklist 
drawn up by each patient regarding their daily schedule and side 
effects of the medication. Capsule counting was also done during 
the study. According to the checklist and capsule counting, we 
excluded 4 patients that showed noncompliance more than twice 
a week.
 Data Analysis 
 The Hardy-Weinberg equilibrium for genotype frequencies in 
MDD patients was calculated using   2 tests. Of the remaining 84 
patients, a small number of missing values on both the depressive 
and anxiety scales existed. Because of this small number, the val-
ues were not modified by intent to treat, such as the last-observa-
tion-carried-forward method. To consider the number of miss-
ing values from each scale, we tabulated the number of subjects 
who were used in the statistical analysis of each scale. Addition-
ally, to confirm our data, we also used repeated measures ANO-
VA to find out the relationship between 0-, 1- and 4-week chang-
es of each measurement over time and across genotypes. These 
factors were a main effect of time (which indicated whether 
changes in an outcome variable occurred as a function of time, 
irrespective of genotypes) and a time  ! treatment interaction 
(which indicated whether changes in subjects over time differed 
between genotypes). Categorical data were analyzed using the   2 
test. Odds ratios (OR) with a 95% CI were calculated to estimate 
the effects of high-risk genotypes and alleles. Logistic regression 
analysis was used to determine the predictors of venlafaxine 
treatment response or remission. The cutoff probability value 
was set at 0.05. SPSS (PC version 13) and was used for statistical 
analysis. This study had the power (0.8) to detect a medium effect 
size (w = 0.33) between 2 genotypes (s/s vs. non-s/s) of 5-HTTLPR 
(  = 0.05).
 Results 
 Sociodemographic Characteristics 
 The sociodemographic characteristics of the MDD pa-
tients are listed as below: male/female ratio of 40 (40%)/61 
(60%), and age of 44.6  8 17.0 years. Each genotype dis-
tribution of the 5-HTTLPR and 5-HTTVNTR polymor-
phism genotypes was in Hardy-Weinberg equilibrium 
(all p  1 0.05).
 A total of 101 subjects with MDD had been recruited. 
Twenty-three patients (22%) were comorbid with dysthy-
mic disorders. Twenty-nine patients (29%) had disorders 
of the melancholic type, and 5 patients (5%) had atypical 
types. Of the 101 patients enrolled, 17 did not complete 
the study: 8 patients because of side effects, 1 patient be-
cause of inefficacy, 4 patients because of partial compli-
ance as determined by a compliance checklist and 4 pa-
tients without explanation. Eighty-four MDD patients 
remained in this study. The baseline scores for age, sex 
and initial HAM-D between patients who dropped out 
and those remaining in this study at 4 weeks were not 
significantly different.
 Venlafaxine Short-Term Treatment Response and 
Genotype Distribution of 5-HTTLPR Polymorphism 
 There were significant differences in the 5-HTTLPR 
genotype distribution between responders and nonre-
sponders divided by HAM-D (  2 = 7.5; p = 0.006), MADRS 
(  2 = 11.7; p = 0.0006) and BDI (  2 = 6.0; p = 0.01) at 4 
weeks. That is, the non-s/s genotype showed a significant 
association with responders for each of the 4-week scale 
scores ( table 1 ). There was also a significant difference in 
the 5-HTTLPR genotype distribution between respond-
ers and nonresponders divided by HAM-A at 4 weeks
(  2 = 7.5; p = 0.006). However, no significant difference 
existed between responders and nonresponders by BAI 
(  2 = 7.5; p = 0.006) ( table 2 ). To consider the 0-, 1- and 
4-week serial changes of measurements over time, repeat-
ed measures ANOVA was also used and showed signifi-
cant genotype  ! time interaction in 3 scales, BDI (F = 
3.4; d.f. = 2, 162; p = 0.03), MADRS (F = 15; d.f. = 2, 156; 
p  ! 0.001) and HAM-A (F = 4.5; d.f. = 2, 152; p = 0.01) 
between non-s/s genotype and s/s genotype after the time 
effects were significantly shown in all each scales (F = 39, 
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d.f. = 2, 162, p  ! 0.001; F = 59, d.f. = 2, 156, p  ! 0.001; F = 
178, d.f. = 2, 152, p  ! 0.001, respectively). That is, the 
scores of the BDI, MADRS and HAM-A significantly de-
creased in patients with the non-s/s genotype  ! time in-
teraction type compared to those with the s/s genotype. 
In terms of the HAM-D, a trend-level genotype  ! time 
interaction showed (F = 2; d.f. = 2, 160; p = 0.07) after the 
time effects had been significant (F = 303; d.f. = 2, 160;
p  ! 0.001) ( table 3 ). However, there is no association be-
tween 5-HTTVNTR and short-term treatment response 
Table 2. Venlafaxine treatment response of anxiety symptoms and genotype and allele frequencies of the 5-
H T T LPR polymorphism in patients with MDD
 Genotype, n
l/l l/s non-s/s s/s
BAI
Responder (n = 47) 3 (6) 19 (40) 22 (46) 25 (54)
Nonresponder (n = 36) 2 (5) 8 (22) 10 (27) 26 (73)
2 = 3.11, d.f. = 1, p = 0.08,
OR = 2.29, CI = 0.91–5.78
HAM-A
Responder (n = 52) 4 (7) 23 (43) 27 (50) 27 (50)
Nonresponder (n = 27) 0 (0) 5 (19) 5 (19) 22 (81)
2 = 7.5, d.f. = 1, p = 0.006,
OR = 4.40, CI = 1.45–13.32
Va lues in parentheses denote percentages.
Table 1.  Venlafaxine treatment response of depressive symptoms and genotype and allele frequencies of the 
5-HTTLPR polymorphism in patients with MDD
G enotype, n
l/l l/s non-s/s s/s
BDI
Responder (n = 42) 4 (9) 18 (43) 22 (52) 20 (47)
Nonresponder (n = 42) 1 (2) 10 (24) 11 (26) 31 (74)
2 = 6.0, d.f. = 1, p = 0.01,
OR = 3.10, CI = 1.24–7.75
HAM-D
Responder (n = 54) 4 (7) 23 (43) 27 (50) 27 (50)
Nonresponder (n = 27) 0 (0) 5 (19) 5 (19) 22 (81)
2 = 7.5, d.f. = 1, p = 0.006,
OR = 4.40, CI = 1.45–13.32
MADRS
Responder (n = 47) 2 (4) 24 (51) 26 (56) 21 (45)
Nonresponder (n = 34) 2 (6) 4 (12) 6 (18) 28 (82)
2 = 11.7, d.f. = 1, p = 0.0006,
OR = 5.78, CI = 2.02–16.56
Val ues in parentheses denote percentages.
D
ow
nl
oa
de
d 
by
: 
Yo
ns
ei
 U
ni
ve
rs
ity
12
8.
13
4.
20
7.
85
 - 
1/
7/
20
14
 3
:2
8:
26
 A
M
 Lee  /Choi  /Lee  /Seok  /Lee  /Lee  /  Kim
 
Neuropsychobiology 2010;62:198–206 202
to venlafaxine by both   2 analysis ( table 4 ) and repeated 
measures ANOVA; BDI (F = 2.05; d.f. = 1, 83; p = 0.16), 
BAI (F = 0.66; d.f. = 1, 83; p = 0.42), MADRS (F = 3.24; 
d.f. = 1, 78; p = 0.08), HAM-D (F = 2.44; d.f. = 1, 80; p = 
0.12) and HAM-A (F = 2.01; d.f. = 1, 78; p = 0.16). There 
also was no significant difference in the genotype distri-
butions of 5-HTTLPR or 5-HTTVNTR between remit-
ters and nonremitters at 4 weeks ( table 5 ).
 The total number of subjects who experienced any 
kind of side effect during the 4-week treatment period 
was 60 (71.43%). The side effects reported in more than 
15% of the subjects were as follows: gastrointestinal (n = 
29; 34.52%); sexual (n = 18; 21.43%); nose, mouth and 
throat (n = 17; 20.24%); neurological (n = 15; 17.86%) and 
sleep related (n = 13; 15.48%). There were no significant 
associations between 5-HTTLPR or 5-HTTVNTR and 
those side effects (all p  1 0.05; data not presented).
 Prediction of Venlafaxine Treatment Response at 4 
Weeks Using Logistic Regression Analysis  
 Table 5 summarizes the results of the logistic regres-
sion analysis, illustrating the possibility of using the 
5-HTTLPR genotype as a predictor of venlafaxine treat-
ment response. Multivariate logistic regression analyses 
Table 3.  Differences in depressive and anxiety symptom severity between s/s and non-s/s genotypes of 5-HTTLPR at baseline, week 1 
and week 4 (scores)
Week 0 Week 1 W eek 4
s/s non-s/s s/s non-s/s s/ s non-s/s
BDI 31.40811.63 30.46812.65 24.87811.36 21.2488.19 18.34814.00 12.0388.77
MADRS 33.8587.03 35.56810.32 26.1688.53 23.1786.80 18.45811.58 10.7888.24
HAM-D 28.1987.02 27.0686.56 20.8386.67 18.1785.20 13.4888.54 9.2886.68
BAI 30.42817.39 26.38814.84 24.14813.79 18.56810.93 17.86814.76 10.7589.49
HAM-A 26.6089.23 24.6588.39 20.4987.93 16.2385.82 14.3889.44 7.8185.91
Val ues are means 8 SD.
Table 4.  Venlafaxine treatment response of depressive and anxiety symptoms and genotype distribution of the 
5-HTTVNTR polymorphism in patients with MDD
G enotype, n 2 and OR
12 /12 non-12/12
BDI
Responder (n = 42) 36 (85) 6 (15) 2 = 0.24, d.f. = 1, p = 0.55
Nonresponder (n = 42) 34 (81) 8 (19) OR = 1.41, CI = 0.44–4.49
HAM-D
Responder (n = 55) 47 (85) 8 (15) 2 = 0.23, d.f. = 1, p = 0.63
Nonresponder (n = 28) 25 (89) 3 (11) OR = 0.71, CI = 0.17–2.90
MADRS
Responder (n = 47) 39 (83) 8 (17) 2 = 1.10, d.f. = 1, p = 0.28
Nonresponder (n = 34) 31 (91) 3 (9) OR = 0.47, CI = 0.12–1.93
BAI
Responder (n = 47) 38 (81) 9 (19) 2 = 0.40, d.f. = 1, p = 0.53
Nonresponder (n = 36) 31 (86) 5 (14) OR = 0.68, CI = 0.21–2.24
HAM-A
Responder (n = 53) 46 (87) 7 (13) 2 = 0.02, d.f. = 1, p = 0.89
Nonresponder (n = 28) 24 (86) 4 (14) OR = 1.10, CI = 0.29–4.12
Val ues in parentheses denote percentages.
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utilized venlafaxine treatment response according to de-
pressive scales such as the BDI, HAM-D and MADRS as 
dependent variables and with variables showing a signif-
icant correlation with the treatment response of each 
scale as covariates. The results revealed a significant as-
sociation of the 5-HTTLPR genotype distribution with 
treatment response on all scales ( table 6 ).
 Discussion 
 The purpose of this study was to determine the rela-
tionship between the 5-HTT polymorphisms and venla-
faxine treatment response. Since the 5-HTT polymor-
phisms, especially 5-HTTLPR, have been suggested to be 
predictors of SSRI treatment response, and given that 
venlafaxine is a potent inhibitor of serotonergic reuptake, 
Table 5.  Remission state by HAM-D and genotype distributions of 5-HTTLPR and 5-HTTVNTR
G enotype, n
l/l l/s non-s/s s/s
5-HTTLPR
Remitter (n = 26) 2 (6) 12 (40) 14 (46) 22 (54)
Nonremitter (n = 58) 2 (5) 16 (22) 18 (27) 40 (73)
2 = 0.61, d.f. = 1, p = 0.43
OR = 1.41, CI = 0.60–3.35
12/12 non-12/12
5-HTTVNTR
Remitter (n = 26) 20 (77) 6 (23)
Nonremitter (n = 58) 51 (88) 7 (12)
2 = 1.6, d.f. = 1, p = 0.20
OR = 2.19, CI = 0.65–7.31
Val ues in parentheses denote percentages.
Table 6.  Prediction of venlafaxine treatment response using logistic regression analysis
R2  d.f. p OR
BDI
Genotype 0.17 1.0 1 0.02 0.3
BDI-0w 0.04 1 0.03 1.0
Sex; age 0.1; 0.0 1 NS 0.8; 0.9
HAM-D
Genotype 0.23 1.7 1 0.00 0.17
Sex; age; HAM-D-0w 0.5; 0.1; 0.1 1 NS 1.7; 0.9; 1.0
MADRS
Genotype 0.29 1.1 1 0.02 0.3
Sex 1.3 1 0.02 0.27
Age; MADRS-0w 0.02; 0.01 1 NS 0.9; 0.9
HAM-A
Genotype 0.28 2.1 1 0.00 0.01
Sex; age; HAM-A-0w 0.5; 0.0; 0.0 1 NS 1
0 w = Score at week 0; NS = not significant.
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a hypothesis that venlafaxine treatment response could 
be related to a 5-HTT polymorphism has been put forth. 
Our results indicate that the non-s/s genotype (l/l + l/s) 
of the 5-HTTLPR polymorphism might be associated 
with better short-term treatment response to venlafaxine. 
These results are supported by previous reports that the 
non-s/s genotype is associated with good treatment re-
sponse  [4] . The mechanism behind these results can be 
assumed according to the following findings. First, the 
capability of the l-allele lymphoblast with respect to sero-
tonin transport is twice as high as that of the s-allele lym-
phoblast  [29] , and transcriptional activity, which is regu-
lated by protein kinase A or C, is better in l-allele plasma 
platelets  [30] . Secondly, transport efficacy (V max /K m ), 
which is the maximum velocity of serotonin transport 
per substrate utilization, is lower in subjects with the s-
allele  [29] . Thirdly, proinflammatory cytokines, which 
promote the expression of the serotonin transporter, can 
be activated in the presence of the l-allele  [31] .
 In contrast, some researchers have reported that the s/s 
genotype or s-allele is associated with good treatment re-
sponse to SSRI, especially in Asian populations  [7, 8] . 
Others could not find any significant association be-
tween 5-HTTLPR and treatment response to SSRI  [5] . 
The discrepancy between those findings and our results 
may stem from the following. First, since the mechanisms 
of action of the SNRI, the treatment response to venlafax-
ine can be different from the response to SSRI, as in the 
milnacipran report  [16] . Second, differences in ethnicity, 
symptom severity, duration of treatment, and time points 
of assessment between this study and previous studies 
could also be a source of inconsistent results. Recently, 
Mrazek et al.  [3] found that the l/l genotype had a greater 
likelihood of remission after citalopram treatment in 
only white non-Hispanic subjects but not in white His-
panic or black subjects. Similar to our study, some other 
Asian studies showed the association between the non-s/s 
or l allele of 5-HTTLPR and good response to SSRI  [9, 15, 
32] . Considering these inconsistent results, further stud-
ies using larger sample sizes in various ethnic popula-
tions are required in order to verify this relationship.
 Although the number of subjects in our study is small, 
our results suggest that 5-HTTLPR polymorphism can 
act as a predictor of venlafaxine treatment response. Our 
study indicated that the side effects of venlafaxine were 
not associated with 5-HTTLPR or genotype distribution. 
This result is consistent with previous studies  [13, 14] that 
reported no association between the 5-HTTLPR and side 
effects of SRIs. However, a recent meta-analysis  [33] sug-
gested the strong relationship between 5-HTTLPR and 
side effects of SSRIs. This discrepancy might come from 
different ethnicities or the different kinds of anti-depres-
sants (mainly SSRIs vs. venlafaxine) used in studies. In 
addition, because the sample size in our study is much 
smaller than that study, our study could not have enough 
power to detect such an association between 5-HTTLPR 
and side effects.
 In this study, 5-HTTVNTR genotypes showed no sig-
nificant association with treatment response. This result 
is partially in line with previous reports  [34, 35] . How-
ever, a meta-analysis  [33] reported that the 12/12 geno-
type showed a trend toward a better response in Asians. 
Recently, Mrazek et al.  [3] reported that in white non-
Hispanic subjects, 5-HTTVNTR was associated with re-
mission following treatment with citalopram. Howev-
er, they also could not find any association between 
5-HTTVNTR and remission in white, Hispanic or black 
subjects. Those findings suggest that the genetic effects of 
5-HTTVNTR on the response or adverse reaction to an-
tidepressants can be different according to study popula-
tions. However, some Korean studies also reported the 
association between the l/l genotype of 5-HTTVNTR 
and better response to SSRI  [7] although they did not use 
venlafaxine. Therefore, further investigations of large 
samples in various populations are needed.
 This study has several limitations. First, due to the 
limited number of subjects in the study population, the 
present study can only be regarded as a pilot study and it 
should be replicated in a larger sample. Considering the 
small number of subjects who were remitted on the 4th 
week or who experienced side effects, we could not find 
any association between the two genes and remission or 
side effects due to the insufficient statistical power of this 
study. Second, this study only evaluated short-term treat-
ment responses in MDD patients after 4 weeks of drug 
administration. However, since a systemic analysis sug-
gested that early treatment response can extend to long-
term treatment response, some researchers have insisted 
that 4 weeks is enough to establish treatment response 
 [36] . Third, we analyzed only two single-nucleotide poly-
morphisms (SNPs) of 5-HTTLPR and 5-HTTVNTR. 
However, other variants such as a functional SNP rs25531 
have been reported to be associated with treatment re-
sponse  [37] . Therefore, further large-scale studies using 
tag SNPs which cover the entire gene region as well as the 
other variations that are supposed to have functional im-
plications are needed. Fourth, we evaluated a relatively 
low dose (fixed dose of 150 mg) for venlafaxine treatment 
response; however, it is known that the serotonergic ac-
tivity of venlafaxine is potent at a relatively low dose  [38, 
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39] , and so we thought that 150 mg would be sufficient to 
evaluate the relationship between the serotonergic gene, 
5-HTTLPR, and treatment response. Fifth, the associa-
tion of 5-HTTLPR with venlafaxine response should be 
examined in a placebo-controlled study. We cannot rule 
out the presence of a population-based stratification bias 
in the present study. Finally, plasma levels of venlafaxine 
were not analyzed in these patients. Thus, we do not 
know exactly the conditions of the drug metabolism. Al-
though we excluded poor drug compliance by a self-re-
port checklist, there might potentially be additional non-
compliant patients in this study.
 In conclusion, this study has demonstrated that the 
non-s/s (l/s + l/l) 5-HTTLPR genotype is associated with, 
and can act as a predictor of, better treatment response to 
venlafaxine. However, these findings require confirma-
tion via well-designed studies utilizing larger samples be-
fore 5-HTTLRP genotyping is considered in the routine 
clinical evaluation of MDD patients using venlafaxine.
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